prasterone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
androgens/anabolic steroids 795 53-43-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • intrarosa
  • 5,6-didehydroepiandrosterone
  • androstenolone
  • dehydroandrosterone
  • dehydroepiandrosterone
  • dehydroisoandrosterone
  • prasterone
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
  • Molecular weight: 288.43
  • Formula: C19H28O2
  • CLOGP: 3.07
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 37.30
  • ALOGS: -3.82
  • ROTB: 0

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
6.50 mg V

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Butterfly rash 104.40 20.38 21 2563 953 46682525
Off label use 73.48 20.38 97 2487 379744 46303734
Periorbital oedema 70.13 20.38 21 2563 5014 46678464
Photosensitivity reaction 57.86 20.38 23 2561 12769 46670709
Swelling face 42.80 20.38 30 2554 53029 46630449
Head discomfort 41.26 20.38 17 2567 10334 46673144
Tinnitus 40.93 20.38 23 2561 27650 46655828
Feeling hot 39.13 20.38 25 2559 37903 46645575
Therapeutic response unexpected 34.56 20.38 17 2567 15599 46667879
Application site discharge 32.94 20.38 6 2578 159 46683319
Hypothalamic pituitary adrenal axis suppression 32.91 20.38 6 2578 160 46683318
Vaginal discharge 30.23 20.38 11 2573 4797 46678681
Dehydroepiandrosterone increased 26.41 20.38 3 2581 0 46683478
Adrenocortical insufficiency acute 25.09 20.38 7 2577 1299 46682179
Granulomatous liver disease 23.32 20.38 6 2578 820 46682658
Cellulitis 21.83 20.38 23 2561 70265 46613213

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC A14AA07 ALIMENTARY TRACT AND METABOLISM
ANABOLIC AGENTS FOR SYSTEMIC USE
ANABOLIC STEROIDS
Androstan derivatives
ATC G03EA03 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION
Androgens and estrogens
ATC G03XX01 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Other sex hormones and modulators of the genital system
MeSH PA D000276 Adjuvants, Immunologic
MeSH PA D007155 Immunologic Factors
CHEBI has role CHEBI:50113 androgens
CHEBI has role CHEBI:75771 mus musculus metabolite
CHEBI has role CHEBI:77746 h. sapiens metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Systemic lupus erythematosus indication 55464009 DOID:9074
Dyspareunia indication 71315007

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
6.5MG INTRAROSA MILLICENT N208470 Nov. 16, 2016 RX INSERT VAGINULLL Nov. 16, 2021 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sex hormone-binding globulin Secreted Kd 7.84 CHEMBL
Glucose-6-phosphate 1-dehydrogenase Enzyme Ki 5.21 CHEMBL
Corticosteroid-binding globulin Secreted Ki 5 CHEMBL
Glucose-6-phosphate 1-dehydrogenase Enzyme Ki 5.96 CHEMBL

External reference:

IDSource
4021360 VUID
N0000148779 NUI
D08409 KEGG_DRUG
4021360 VANDF
4036745 VANDF
C0011185 UMLSCUI
CHEBI:28689 CHEBI
AND PDB_CHEM_ID
CHEMBL90593 ChEMBL_ID
DB01708 DRUGBANK_ID
5881 PUBCHEM_CID
D003687 MESH_DESCRIPTOR_UI
2370 IUPHAR_LIGAND_ID
2869 INN_ID
459AG36T1B UNII
1927689 RXNORM
131731 MMSL
20676 MMSL
247058 MMSL
32118 MMSL
73034 MMSL
d04425 MMSL
004609 NDDF
413963008 SNOMEDCT_US
78316004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Intrarosa HUMAN PRESCRIPTION DRUG LABEL 1 64011-601 INSERT 6.50 mg VAGINULLL NDA 17 sections
Intrarosa HUMAN PRESCRIPTION DRUG LABEL 1 72495-401 INSERT 6.50 mg VAGINULLL NDA 17 sections
Intrarosa HUMAN PRESCRIPTION DRUG LABEL 1 72495-501 INSERT 6.50 mg VAGINULLL NDA 17 sections